First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology
May 22 2024 - 8:42AM
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for
minimally invasive endovascular intervention, today announced that
Hospital Santa Maria della Pietà, in Nola in the Metropolitan City
of Naples, has established the first robotic cardiac heart program
in Southern Italy. Patients suffering from heart rhythm disorders
are now being successfully treated with robotic ablation procedures
using this advanced technology, and Hospital Santa Maria della
Pietà is the first hospital in Italy to adopt the cutting-edge
Genesis Robotic Magnetic Navigation (RMN) system.
“As electrophysiologists, our primary goal is to
improve the lives of our patients,” said Dr. Mario Volpicelli, Head
of the Electrophysiology Unit of the hospital. “With the Genesis
RMN system, we now have an unprecedented level of precision and
control during cardiac ablation procedures, allowing us to target
arrhythmias with unmatched accuracy while minimizing risk to our
patients.”
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias –
abnormal heart rhythms that result when the heart beats too
quickly, too slowly, or with an irregular pattern. When left
untreated, arrhythmias may significantly increase the risk of
stroke, heart failure, and sudden cardiac arrest.
"The adoption of the Genesis Robotic Magnetic
Navigation system marks a significant milestone in our commitment
to providing the highest standard of care to our patients.” added
Giuseppe Russo, General Manager of the Hospital Santa Maria della
Pietà.
“We are proud to lead the way in Italy,
revolutionizing cardiac treatment through innovative robotic
technology." added Luigi Caliendo, Chief of the Cardiology
Department of the Hospital.
“We are honored to partner with Hospital Santa
Maria della Pietà in bringing the benefits of robotics to patients
in Italy,” said David Fischel, Stereotaxis Chairman and CEO. “The
adoption of the Genesis system reflects our shared commitment to
advancing standard of care, innovation, and patient-focused
solutions in electrophysiology.”
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts: David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Aug 2023 to Aug 2024